Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells

BACKGROUND/AIMS: Nilotinib is used for treating patients with imatinib-sensitive or -resistant chronic myeloid leukemia (CML); however, nilotinib-resistant cases have been observed in recent years. In addition, a considerable number of patients receiving nilotinib developed diabetes. Metformin is a...

Descripción completa

Detalles Bibliográficos
Autores principales: Na, Yoo Jin, Yu, Eun Sang, Kim, Dae Sik, Lee, Dae-Hee, Oh, Sang Cheul, Choi, Chul Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Internal Medicine 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009173/
https://www.ncbi.nlm.nih.gov/pubmed/32241082
http://dx.doi.org/10.3904/kjim.2019.336

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009173/
https://www.ncbi.nlm.nih.gov/pubmed/32241082
http://dx.doi.org/10.3904/kjim.2019.336

Ejemplares similares